Enzene Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
976
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$50M
- Investors
-
3
Enzene General Information
Description
Operator of a biotechnology company intended to provide affordable medicines to the market at speed. The company utilizes good manufacturing practices (GMP) processes and helps in cloning, process development, and novel formulation development, enabling clients and companies in commercial microbial manufacturing to harness disruptive innovation to enhance global healthcare.
Contact Information
Website
www.enzene.comCorporate Office
- Plot Number A 22, A/1/2 Chakan Industrial Area
- Phase 2, Khalumbre, Chakan
- Pune, Maharashtra 410501
- India
Corporate Office
- Plot Number A 22, A/1/2 Chakan Industrial Area
- Phase 2, Khalumbre, Chakan
- Pune, Maharashtra 410501
- India
Enzene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 29-Jan-2023 | $50M | Completed | Generating Revenue |
Enzene Comparisons
Industry
Financing
Details
Enzene Competitors (9)
One of Enzene’s 9 competitors is Phenomic AI, a Venture Capital-Backed company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Phenomic AI | Venture Capital-Backed | Toronto, Canada | ||||
| Progenra | Formerly VC-backed | Malvern, PA | ||||
| Lakefront Biotherapeutics | Formerly VC-backed | Mechelen, Belgium | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Cantex Pharmaceuticals | Formerly VC-backed | Weston, FL |
Enzene Patents
Enzene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026132955-A1 | Green solvent-based mixed-solvent strategy for the synthesis of peptide | Pending | 19-Dec-2024 | ||
| US-20250320267-A1 | Methods of making recombinant il-12/il-15 albumin binding domain fusion proteins | Pending | 12-Apr-2024 | ||
| WO-2024257040-A1 | Composition and stable liquid formulations comprising humanized anti-human interleukin 6 (il-6) receptor monoclonal antibodies | Inactive | 14-Jun-2023 | ||
| AU-2024260197-A1 | In line cleaning in place process for alternating tangential flow filter | Pending | 25-Apr-2023 | ||
| EP-4702122-A1 | In line cleaning in place process for alternating tangential flow filter | Pending | 25-Apr-2023 | C12M39/00 |
Enzene Signals
Enzene Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alkem Laboratories | Corporation | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority |
Enzene FAQs
-
When was Enzene founded?
Enzene was founded in 2006.
-
Where is Enzene headquartered?
Enzene is headquartered in Pune, India.
-
What is the size of Enzene?
Enzene has 976 total employees.
-
What industry is Enzene in?
Enzene’s primary industry is Biotechnology.
-
Is Enzene a private or public company?
Enzene is a Private company.
-
What is Enzene’s current revenue?
The current revenue for Enzene is .
-
How much funding has Enzene raised over time?
Enzene has raised $50M.
-
Who are Enzene’s investors?
Alkem Laboratories, Eight Roads, and F-Prime have invested in Enzene.
-
Who are Enzene’s competitors?
Phenomic AI, Progenra, Lakefront Biotherapeutics, Nurix Therapeutics, and Cantex Pharmaceuticals are some of the 9 competitors of Enzene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process